Steven de Maat

Steven de Maat has had a varied and extensive career in biopharmaceuticals, research, and development. In 2007, they began their career as a Non-Affiliated Student Technician at Texas A&M University's Lab of James E. Samuel, where they conducted research on the intra cellular bacteria Coxiella burnetii. In 2009, they joined the Universiteit Utrecht as a Student Assistent in the Department of Cellular Architecture and Dynamics, where they were involved in research involving multiple projects, including VHH production, ELISA, and Cell Culture. In 2010, they were a Graduate Student in the same department, where they applied Nile Red and LD540 in the detection of lipid droplets within FHSD muscle tissue using iLEM. In 2011, Steven became a Postdoctoraal Onderzoeker at UMC Utrecht, where they investigated the physiological role of the protein 'factor XII' in health and disease, developing new bioassays and a diverse range of recombinant factor XII proteins. In 2017, they Co-Founded SERPINx. In 2018, Steven Co-Founded TargED Biopharmaceuticals, where they are currently Chief Scientific Officer and is developing the biopharmaceutical product MICROLYSE, which enzymatically breaks down blood clots in small blood vessels.

Steven de Maat attended HU University of Applied Sciences Utrecht (Hogeschool Utrecht) from 2004 to 2008, where they earned a Bachelor of Applied Science (B.A.Sc.) in Life Sciences - Molecular biology. Steven then attended Utrecht University from 2008 to 2011, where they earned a Master of Science (M.Sc.) in Biomolecular Sciences. Finally, they attended Utrecht University from 2011 to 2016, where they earned a Doctor of Philosophy - PhD.